focus -WSS

focus

author：hotspot 2025-09-27 22:47:14 - browse：836

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： At ASCO, AstraZeneca reports strong data for breast cancer drug

WSS

After sickle

NIH documents show early flaws of $1.6 billion long Covid program

Radiology is caught between AI's potential and concern for patients

FDA's Pazdur wants cancer trials to range beyond China alone

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

CMS should re

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

The cancer drug shortage isn’t new — and neither are the solutions

摘要：有人认为，在线教育现在正像学区房一样悄无声息地成为家长们比拼财富的赛场，甚至是加速着贫富分化。

The cancer drug shortage isn’t new — and neither are the solutions

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Anesthesiologist group: stop taking Ozempic before surgery

Pharma patents targeted by Biden in move to slash drug prices

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

STAT letters to the editor on burnt

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

knowledge

FDA needs staff influx to meet gene therapy needs, Marks says

HIV drugs protect against transmission, even in unprotected sex

Woman returns to dialysis after doctors remove transplanted pig kidney

Let's speed up science by embracing open access publishing

Pfizer plans to depart BIO

Congenital heart disease patients face new threat of heart failure

leisure time

leisure time

hotspot

hotspot